Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alpha Cognition Inc (ACOG)

Alpha Cognition Inc (ACOG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 151,112
  • Shares Outstanding, K 21,774
  • Annual Sales, $ 10,220 K
  • Annual Income, $ -20,670 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 2.51
  • Price/Sales 14.17
  • Price/Cash Flow N/A
  • Price/Book 2.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 2
  • High Estimate $-0.28
  • Low Estimate $-0.44
  • Prior Year $-0.20
  • Growth Rate Est. (year over year) -80.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.87 +42.51%
on 03/27/26
7.55 -8.08%
on 04/08/26
+1.18 (+20.49%)
since 03/17/26
3-Month
4.50 +54.22%
on 02/05/26
7.55 -8.08%
on 04/08/26
+1.22 (+21.33%)
since 01/16/26
52-Week
4.20 +65.24%
on 04/21/25
11.54 -39.86%
on 07/10/25
+2.82 (+68.45%)
since 04/17/25

Most Recent Stories

More News
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders,...

ACOG : 6.94 (+4.36%)
Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders,...

ACOG : 6.94 (+4.36%)
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

Alpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million Fourth quarter...

ACOG : 6.94 (+4.36%)
Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Management to host conference call on Thursday, March 26, 2026 at 4:30pm ET

ACOG : 6.94 (+4.36%)
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced...

ACOG : 6.94 (+4.36%)
Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative...

ACOG : 6.94 (+4.36%)
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders,...

ACOG : 6.94 (+4.36%)
Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution

ZUNVEYL prescriber base expected to expand to approximately 2,000 prescribing healthcare providers, and an increase in nursing home penetration Company...

ACOG : 6.94 (+4.36%)
Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced...

ACOG : 6.94 (+4.36%)
Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

Key Highlights ZUNVEYL Launch Momentum: Completed the second quarter of commercialization, generating approximately $2.8 million...

ACOG : 6.94 (+4.36%)

Business Summary

Alpha Cognition Inc. is a clinical stage biopharmaceutical company. It involved in developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. Alpha Cognition Inc. is based in Vancouver, British Columbia.

See More

Key Turning Points

3rd Resistance Point 7.64
2nd Resistance Point 7.35
1st Resistance Point 7.14
Last Price 6.94
1st Support Level 6.65
2nd Support Level 6.36
3rd Support Level 6.15

See More

52-Week High 11.54
Fibonacci 61.8% 8.74
Fibonacci 50% 7.87
Fibonacci 38.2% 7.00
Last Price 6.94
52-Week Low 4.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.